研究婴儿新发作的临床病因概况
N Shanmugapriya1, Prachi Goyal1, Nirbhay Mehta1
1Department of Paediatrics, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India.
Journal of pharmacy & bioallied sciences
|January 12, 2026
概括
发烧性发作是婴儿新发作发作的最常见原因. 大多数婴儿能够控制发作,很少有患有耐药性或发育迟缓的婴儿.
科学领域:
- 儿科 儿科 儿科
- 神经学 神经学
- 临床医学 临床医学
背景情况:
- 婴儿 (1个月-1岁) 新发作的有不同的病因.
- 预后受到潜在原因,发作类型,并发症和遗传因素的影响.
- 系统评估对于诊断,治疗和家长咨询至关重要.
研究的目的:
- 调查婴儿新发作的临床和病因概况.
- 分析1-12个月龄的婴儿的发作类型,出现症状和结果.
主要方法:
- 一项为期12个月的横截面观察研究,对100名患有新发作的婴儿进行了观察.
- 进行了临床评估,EEG,MRI和发育查 (TDSC).
- 使用SPSS版本22分析的数据.
主要成果:
- 发烧发作 (35%) 是最常见的病因,其次是 (21%) 和脑膜炎 (13%).
- 总化的强力克隆性发作占主导地位 (71%).
- 发烧 (52%) 是最常见的症状,11%的发育迟缓,97%的控制.
结论:
- 发烧性发作是婴儿新发作的主要原因.
- 大多数婴儿实现了良好的控制,少数患有耐药性或发育迟缓.
相关概念视频
Seizures: Classification
1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
804
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
804
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
620
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
620


